From Wikipedia, the free encyclopedia
Jump to: navigation, search
Brivaracetam.svg Brivaracetam3d.png
PubChem 9837243
ChemSpider 8012964 YesY
Jmol-3D images Image 1
Molecular formula C11H20N2O2
Molar mass 212.29 g mol−1
Routes of
Legal status


Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY (verify) (what is: YesY/N?)
Infobox references

Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties.[1][2] Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle protein SV2.[3] Phase II clinical trials in adult patients with refractory partial seizures were promising. Positive preliminary results from stage III trials have been recorded,[4][5] along with evidence that it is around 10 times more potent[6] for the prevention of certain types of seizure in mouse models than levetiracetam, of which it is an analogue.


  1. ^ von Rosenstiel P (2007). "Brivaracetam (UCB 34714)". Neurotherapeutics 4 (1): 84–7. doi:10.1016/j.nurt.2006.11.004. PMID 17199019. 
  2. ^ Malawska B, Kulig K (2005). "Brivaracetam UCB". Curr Opin Investig Drugs 6 (7): 740–746. PMID 16044671. 
  3. ^ Rogawski MA, Bazil CW (2008). "New molecular targets for antiepileptic drugs: α2δ, SV2A, and K(v)7/KCNQ/M potassium channels". Curr Neurol Neurosci Rep 8 (4): 345–352. doi:10.1007/s11910-008-0053-7. PMC 2587091. PMID 18590620. 
  4. ^
  5. ^ Rogawski M (2008). "Brivaracetam: a rational drug discovery success story". Br J Pharmacol 154 (8): 1555–7. doi:10.1038/bjp.2008.221. PMC 2518467. PMID 18552880. 
  6. ^